KT Medical Service PCL (BKK:KTMS) Research & Development: ฿0.0 Mil (TTM As of Mar. 2026)


BKK:KTMS KT Medical Service PCL BKK:KTMS
70 GF Score
Price ฿1.31
GF Value ฿3.04
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is KT Medical Service PCL Research & Development?

KT Medical Service PCL BKK:KTMS 70 Research & Development is ฿0.0 Mil as of Mar. 2026. GuruFocus rates BKK:KTMS with a GF Score™ of 70/100 and a GF Value™ of ฿3.04 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. KT Medical Service PCL's Research & Development for the three months ended in Mar. 2026 was ฿0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ฿0.0 Mil.

KT Medical Service PCL  (BKK:KTMS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

KT Medical Service PCL Research & Development Related Terms

KT Medical Service PCL Research & Development Historical Data

* Premium members only.

The historical data trend for KT Medical Service PCL's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KT Medical Service PCL Research & Development Chart

KT Medical Service PCL Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

KT Medical Service PCL Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BKK:KTMS
70GF Score
KT Medical Service PCL BKK:KTMS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

KT Medical Service PCL Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ฿0.0 Mil mean?
KT Medical Service PCL (BKK:KTMS) has a Research & Development of ฿0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on KT Medical Service PCL and its competitors.
Is KT Medical Service PCL's Research & Development too high?
KT Medical Service PCL's current Research & Development is ฿0.0 Mil. Overall, KT Medical Service PCL has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KT Medical Service PCL's Research & Development compare to HCA and THC?
KT Medical Service PCL's Research & Development of ฿0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on KT Medical Service PCL and its competitors. KT Medical Service PCL's current Research & Development is ฿0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KT Medical Service PCL stock overvalued right now?
Based on GuruFocus' analysis, KT Medical Service PCL (BKK:KTMS) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿3.04, compared to a current price of ฿1.31 — trading 56.9% below its estimated fair value. The current Research & Development is ฿0.0 Mil. KT Medical Service PCL's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For KT Medical Service PCL (BKK:KTMS), the current Research & Development is ฿0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is KT Medical Service PCL (BKK:KTMS) Overvalued in 2026?

Based on GuruFocus' analysis, KT Medical Service PCL stock appears to be undervalued. The current stock price of ฿1.31 is trading 56.9% below its estimated GF Value™ of ฿3.04. GuruFocus considers KT Medical Service PCL to be Significantly Undervalued.

Key valuation signals for BKK:KTMS:

  • Research & Development: ฿0.0 Mil
  • GF Value™: ฿3.04 vs. price of ฿1.31 (56.9% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the BKK:KTMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

KT Medical Service PCL Business Description

Address 95 Soi Ramintra 117, Ramintra Road, Khwaeng Minburi, Khet Minburi, Bangkok, THA, 10510
KT Medical Service PCL operates in Thailand and engages in hemodialysis center, design, assembly and installation of pure water treatment system and service preventive maintenance of pure water treatment system for commercial and residential sectors, the industrial and original equipment manufacturing of water system sector and medical service sector. The company's segments include Service of hemodialysis, Service of design and installation of pure water treatment system and the service preventive maintenance of pure water treatment system for medical service, and Services of design and installation of pneumatic tube system of equipment for medical service. It derives majority of the revenue from Service of hemodialysis segment.
70GF Score

Get the complete analysis for BKK:KTMS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿1.31
Price
฿3.04
GF Value